Cargando…

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs), while having changed the treatment of multiple cancers, come with novel immune-related adverse events (irAEs) resembling autoimmune diseases. The registration data suggest that at least some irAEs have a prognostic nature regarding the efficiency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuusisalo, Saara, Koivunen, Jussi P., Iivanainen, Sanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103509/ https://www.ncbi.nlm.nih.gov/pubmed/35565405 http://dx.doi.org/10.3390/cancers14092276

Ejemplares similares

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies
por: Iivanainen, Sanna, et al.
Publicado: (2021)

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
por: Iivanainen, Sanna, et al.
Publicado: (2020)

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Iivanainen, Sanna, et al.
Publicado: (2019)

The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer
por: Kuusisalo, Saara, et al.
Publicado: (2023)

Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
por: Alanen, Virve, et al.
Publicado: (2020)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
por: Jokimäki, Anna, et al.
Publicado: (2023)

Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
por: Tikkanen, Antti, et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients’ Survival: Single Center Experience and Literature Review
por: Romão, Raquel, et al.
Publicado: (2023)

Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
por: Wu, Si, et al.
Publicado: (2022)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience
por: Kaur, Aneet, et al.
Publicado: (2019)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Assessment of chemotherapy‐induced neurotoxicity using a point‐of‐care nerve conduction study device
por: Jokimäki, Anna, et al.
Publicado: (2022)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
por: Jain, P., et al.
Publicado: (2021)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
por: Hyun, Jae-Won, et al.
Publicado: (2022)

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
por: Ge, Xiaoxiao, et al.
Publicado: (2023)

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
por: Shi, Yuequan, et al.
Publicado: (2021)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
por: Villa-Crespo, Lorena, et al.
Publicado: (2022)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study
por: Iivanainen, Sanna, et al.
Publicado: (2020)

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
por: Van Buren, Inga, et al.
Publicado: (2023)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
por: Wang, Feicheng, et al.
Publicado: (2021)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tull9tqb2ilavr1qjpt1nsvgnn